← All tickers

Is MTNB Worth Buying in 2026?

Matinas BioPharma Holdings, Inc.

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-16

Here’s whether Matinas BioPharma Holdings, Inc. (MTNB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-16.33% over 10 days); RSI 25 — oversold; weak 1-year return of -85.8%; 3-month momentum negative (-58.3%). Currently 92.4% off its 52-week high. Score: -7/7.

Ready to act on this? 📈 Trade on Webull

MTNB is trading below its 200-day MA ($0.66) — a key warning sign the longer-term trend is under pressure. An RSI of 24.7 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -85.8% compares to +20.4% for SPY (trailed the market by 106.2%). The current 92.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $1,418 today
vs. S&P 500 (SPY) — same period trailed market by 106.2%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($0.66)
✗Above 50-day MA ($0.50)
!RSI(14) neutral zone (30–70) — currently 24.7
✗Positive return (-85.8%)
!Within 10% of period high (−92.4%)
Period Range $0.23
$0.22 $3.09
RSI (14) 24.7
0 · OversoldOverbought · 100

Key Metrics

Price$0.23
Period Return-85.8%
Period High$3.09
Period Low$0.22
Drawdown−92.4%
MA-50$0.50
MA-200$0.66
RSI (14)24.7
Avg Volume (30d)10.8M
vs. SPYtrailed by 106.2%
Return Rank#1190 of 1252

Trade MTNB

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers